A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy Participants

November 13, 2026 updated by: Eli Lilly and Company

A Phase 1, Randomized, Placebo-Controlled, Investigator- and Participant-Blinded, Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy Participants

The main purpose of this study is to see if LY3839056 is safe and well tolerated when given as a single dose into a vein intravenous (IV) or under the skin subcutaneous (SC) in healthy participants. The study will also measure how much LY3839056 gets into the blood and how long it takes the body to remove it. The study will last up to 17 weeks and includes a stay of about 6 days at the clinical research unit.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

64

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200040
        • Huashan Hospital, Fudan University (复旦大学附属华山医院) 12 Urumqi Middle Road
        • Contact:
          • Xiaojie Wu, PhD
          • Phone Number: 13524686330

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Key Inclusion Criteria:

  • Are overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and Cardiac Monitoring.
  • Have clinical laboratory test results within normal reference range for the population or the clinical research site, or results with acceptable deviations that are judged to be not clinically significant by the investigator.
  • Have venous access sufficient to allow for IV drug delivery and blood sampling as per the protocol.
  • Have a body mass index within the range of 18.0 to 32.0 kg/m².
  • Participants assigned male or female at birth, including individuals of childbearing potential (IOCBP), may participate in this trial.
  • Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies

Key Exclusion Criteria:

  • Are immunocompromised or have a history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection.
  • Have a history or presence of cardiovascular, respiratory, hepatic, ophthalmological, renal, gastrointestinal, endocrine, hematological, neurological, or psychiatric disorders.
  • Had any surgical procedure (except for minor surgery requiring local or no anesthesia and without any complications or sequelae) within 12 weeks prior to screening, or any planned surgical procedure scheduled to occur during the study.
  • Have a clinically significant history of multiple or severe allergies or an anaphylactic reaction to prescription or nonprescription drugs or food.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cohort 1 IV

Participants will receive LY3839056 Intravenously

LY3839056 Administered Intravenously

Other Names:
  • LY3839056 Administered IV
Experimental: Cohort 2 IV

Participants will receive LY3839056 Intravenously

LY3839056 Administered Intravenously

Other Names:
  • LY3839056 Administered IV
Experimental: Cohort 3 IV

Participants will receive LY3839056 Intravenously

LY3839056 Administered Intravenously

Other Names:
  • LY3839056 Administered IV
Experimental: Cohort 4a IV

Participants will receive LY3839056 Intravenously

LY3839056 Administered Intravenously

Other Names:
  • LY3839056 Administered IV
Experimental: Cohort 4b SC

Participants will receive LY3839056 Subcutaneously

LY3839056 Administered Subcutaneously

Other Names:
  • LY3839056 Administered SC
Experimental: Cohort 5 IV

Participants will receive LY3839056 Intravenously

LY3839056 Administered Intravenously

Other Names:
  • LY3839056 Administered IV
Experimental: Cohort 6a IV

Participants will receive LY3839056 Intravenously

LY3839056 Administered Intravenously

Other Names:
  • LY3839056 Administered IV
Experimental: Cohort 6b SC

Participants will receive LY3839056 Subcutaneously

LY3839056 Administered Subcutaneously

Other Names:
  • LY3839056 Administered SC
Placebo Comparator: Placebo IV

Participants will receive Placebo Intravenously

Placebo Administered Intravenously

Other Names:
  • Placebo Administered IV
Placebo Comparator: Placebo SC

Participants will receive Placebo Subcutaneously

Placebo Administered Subcutaneously

Other Names:
  • Placebo Administered SC

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To evaluate the safety and tolerability of LY3839056 following single-dose administration (IV or SC) in healthy participants.
Time Frame: Baseline through Day 85

Frequency of AEs, TEAEs, SAEs, and Discontinuation due to TEAEs.

Baseline through Day 85

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PK: Cmax
Time Frame: Predose on Day 1 up to Day 85

Maximum Observed Concentration (Cmax) of LY3839056 following single SC or IV dose

Predose on Day 1 up to Day 85
PK: AUC
Time Frame: Predose on Day 1 up to Day 85

Area Under the Concentration Versus Time Curve (AUC) of LY3839056 following single SC or IV dose

Predose on Day 1 up to Day 85
PK: t1/2
Time Frame: Predose on Day 1 up to Day 85

Half Life (t1/2) of LY3839056 following single SC or IV dose

Predose on Day 1 up to Day 85
PK: F%
Time Frame: Predose on Day 1 up to Day 85

Bioavailability (F%) of LY3839056 following single SC dose

Predose on Day 1 up to Day 85

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

November 13, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 27924
  • J7H-MC-KAAB (Other Identifier: Eli Lilly and Company)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.